市場調查報告書
商品編碼
1028279

中國的Venlafaxine市場(2021年∼2025年)

Research Report on China's Venlafaxine Market, 2021-2025

出版日期: | 出版商: China Research and Intelligence | 英文 40 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

2020年由於COVID-19的影響,中國的醫療機關無法正常運作,Venlafaxine的銷售額比2019年減少,約成為2億9,400萬人民幣(4,520萬美元),從2016年到2020年期間的年複合成長率為約7.4%。中國的Venlafaxine市場,因為COVID-19在中國受控制,從2021年到2025年預計成長。

由於經濟的發展,都市化的發展,工作速度的加速,人際關係的變化等造成中國居民的生活壓力高漲,中國的憂鬱症患者數今後也將增加,預計中國市場中含Venlafaxine的抗憂鬱劑的銷售量及銷售額逐年逐漸增加。

本報告提供中國的Venlafaxine市場的相關調查,市場規模和預測,市場動態,COVID-19的影響,開發環境,廠商及市場佔有率,銷售價格等資訊。

目錄

第1章 Venlafaxine的相關概念

  • Venlafaxine的適應症
  • 中國的Venlafaxine市場發展
  • 中國的Venlafaxine的政府核准
  • COVID-19對中國的Venlafaxine市場的影響

第2章 中國的Venlafaxine銷售(2016-2020)

  • 銷售額
    • 中國的銷售額
    • 各地區:中國的銷售額
  • 銷售量
    • 中國的銷售量
    • 各地區:中國的銷售量
  • 各劑型:中國的Venlafaxine銷售(2016-2020)
    • 緩釋性膠囊
    • 緩釋片
    • 膠囊
    • 其他

第3章 中國的主要Venlafaxinemeka分析(2020)

  • 市場佔有率分析
    • 各銷售額製造商市場佔有率
    • 各銷售量製造商市場佔有率
  • Pfizer Healthcare Ireland
    • 企業簡介
    • 中國的Venlafaxine銷售
  • Chengdu Kanghong Pharmaceutical Group
    • 企業簡介
    • 中國的Venlafaxine銷售
  • Beijing Winsunny Pharmaceutical Co., Ltd
  • Chengdu Beite Pharmaceutical Co.,Ltd
  • Guizhou Salvage Pharmaceutical Co.,Ltd

第4章 各企業的中國的Venlafaxine銷售價格(2020-2021)

  • Pfizer Healthcare Ireland (Effexor XR (R))
  • Chengdu Kanghong Pharmaceutical Group (Bolexin (R))
  • Beijing Winsunny Pharmaceutical Co., Ltd (WenYueSi (R))
  • Chengdu Beite Pharmaceutical Co., Ltd (BeiTe (R))
  • Guizhou Salvage Pharmaceutical Co., Ltd (ShengJiLe (R))

第5章 中國的Venlafaxine市場預測(2021-2025)

  • 市場開發的影響因素
    • COVID-19對市場的影響
    • 市場成長要素和機會
    • 市場威脅與課題
  • 市場規模的預測
  • 市場趨勢的預測
目錄
Product Code: 2109553

Depression is the result of a complex interplay of social, psychological and physical factors. People who experience adverse events in their lives are more likely to develop depression. Depression can lead to greater stress and dysfunction, affecting the life of patients and exacerbating their depressive symptoms.

Depression is the fourth leading disease in the world and is expected to become the first leading one by 2030. However, the medical management of depression in China is still under-recognized, with less than 20% of depressed patients at all levels of hospital care and less than 20% of Chinese depressed patients receiving relevant medication. Moreover, the cases of depression and depression-caused suicides are at a younger age (college, and even primary and secondary school students). According to WHO, more than 350 million people worldwide are suffering from depression, with a growth rate of about 18% over the last decade. It is estimated that, by 2021, the number of people suffering from depression in China is about 95 million.

Current treatment for depression is mainly based on antidepressant medication, supplemented by psychotherapy or physical therapy. serotonin-norepinephrine reuptake inhibitors (SNRIs), as one of the used drugs, are antidepressants used to treat major depressive disorder and other psychiatric disorders.

Venlafaxine was the first approved SNRI inhibitor. It was originally developed by Wyeth, a subsidiary of Pfizer, under the trade name Effexor XR®. The immediate-release form of venlafaxine for the treatment of depression was marketed in the United States in 1994, and later in 1997, the extended-release form of venlafaxine was approved by the FDA. The extended-release form has a smoother onset of action than the immediate-release form and reaches lower peak concentrations, thus causing fewer adverse effects.

According to CRI's market research, in 1998, the generic drug of venlafaxine from Chengdu Kanghong Pharmaceutical Group, Venlafaxine Capsules (trade name: Bolexin®) was launched in China, becoming the first domestic venlafaxine product. The original drug, Pfizer's Effexor XR was not marketed in China until 2001, followed by a number of generic drugs from local Chinese companies. Although Effexor XR was late to enter China's market, it still holds a major market share. In 2020, Effexor XR accounted for about 50% of the market share in China in terms of sales value.

According to CRI's market research, in 2020, because of the impact of COVID-19, Chinese healthcare institutions could not function properly, making the sales value of venlafaxine decrease from that of 2019 to approximately CNY294 million (USD45.2 million), with a CAGR of approximately 7.4% from 2016 to 2020. China's venlafaxine market is expected to see growth from 2021 to 2025 as COVID-19 is under control in China.

CRI expects that the rising stress of Chinese residents' life brought about by the developing economy, rising urbanization, accelerated pace of work and changing interpersonal relationships, the number of depressed patients in China will continue to grow in the future, and the sales volume and value of antidepressants, including venlafaxine, will increase year by year in the Chinese market.

Topics Covered:

Impact of COVID-19 on China's Venlafaxine Market

Development Environment of Venlafaxine in China

Sales Volume of Venlafaxine in China

Sales Volume and Value of Venlafaxine in China by Region

Major Venlafaxine Manufacturers in China and Their Market Shares

Sales Price of Venlafaxine in China

Prospects of China's Venlafaxine Market, 2021-2025

Table of Contents

1 Relevant Concept of Venlafaxine

  • 1.1 Indications of Venlafaxine
  • 1.2 Development of China's Venlafaxine Market
  • 1.3 Governmental Approval of Venlafaxine in China
  • 1.4 The Impact of COVID-19 on China's Venlafaxine Market

2 Sales of Venlafaxine in China, 2016-2020

  • 2.1 Sales Value
    • 2.1.1 Sales Value in China
    • 2.1.2 Sales Value in China by Region
  • 2.2 Sales Volume
    • 2.2.1 Sales Volume in China
    • 2.2.2 Sales Volume in China by Region
  • 2.3 Sales of Venlafaxine in China by Dosage Form, 2016-2020
    • 2.3.1 Extended-Release Capsules
    • 2.3.2 Extended-Release Tablets
    • 2.3.3 Capsules
    • 2.3.4 Other Dosage Forms

3 Analysis of Major Venlafaxine Manufacturers in China, 2020

  • 3.1 Analysis of Market Share
    • 3.1.1 Market Share of Manufacturers by Sales Value
    • 3.1.2 Market Share of Manufacturers by Sales Volume
  • 3.2 Pfizer Healthcare Ireland
    • 3.2.1 Company Profile
    • 3.2.2 Sales of Venlafaxine in China
  • 3.3 Chengdu Kanghong Pharmaceutical Group
    • 3.3.1 Company Profile
    • 3.3.2 Sales of Venlafaxine in China
  • 3.4 Beijing Winsunny Pharmaceutical Co., Ltd
  • 3.5 Chengdu Beite Pharmaceutical Co., Ltd
  • 3.6 Guizhou Salvage Pharmaceutical Co., Ltd

4 Sales Price of Venlafaxine of Different Companies in China, 2020-2021

  • 4.1 Pfizer Healthcare Ireland (Effexor XR®)
  • 4.2 Chengdu Kanghong Pharmaceutical Group (Bolexin®)
  • 4.3 Beijing Winsunny Pharmaceutical Co., Ltd (WenYueSi®)
  • 4.4 Chengdu Beite Pharmaceutical Co., Ltd (BeiTe®)
  • 4.5 Guizhou Salvage Pharmaceutical Co., Ltd (ShengJiLe®)

5 Prospects of China's Venlafaxine Market, 2021-2025

  • 5.1 Influencing Factors for the Market Development
    • 5.1.1 The Impact of COVID-19 on the Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

List of Charts

  • Chart Patent Information of Venlafaxine in China
  • Chart Sales Value of Venlafaxine in China, 2016-2020
  • Chart Sales Volume of Venlafaxine in China, 2016-2020
  • Chart Sales Volume of Venlafaxine in China by Region, 2016-2020
  • Chart Sales Value of Venlafaxine in China by Region, 2016-2020
  • Chart Sales Volume of Venlafaxine Extended-Release Capsules in China, 2016-2020
  • Chart Sales Volume of Venlafaxine Extended-Release Tablets in China, 2016-2020
  • Chart Sales Volume of Venlafaxine Tablets in China, 2016-2020
  • Chart Market Share of Venlafaxine Manufacturers in China by Sales Value, 2016-2020
  • Chart Sales Value and Volume of Venlafaxine (of Pfizer Healthcare Ireland) in China, 2016-2020
  • Chart Sales Value and Volume of (Venlafaxine of Chengdu Kanghong Pharmaceutical Group) in China, 2016-2020
  • Chart Sales Price of Effexor XR (Venlafaxine of Pfizer Healthcare Ireland) in China, 2016-2020
  • Chart Sales Price of Bolexin (Venlafaxine of Chengdu Kanghong Pharmaceutical Group) in China, 2016-2020
  • Chart Forecast on Sales Value of Venlafaxine in China, 2021-2025
  • Chart Forecast on Sales Volume of Venlafaxine in China, 2021-2025